FibroBiologics Inc. (NASDAQ: FBLG) filed a provisional patent application with the U.S. Patent and Trademark Office for oral delivery systems designed to protect fibroblast-based therapeutics through the stomach and enable targeted release in the gastrointestinal tract.

The patent application, titled "Oral Fibroblasts and Fibroblast-Derived Therapeutics and Delivery Systems for Same," describes an oral administration platform intended to deliver fibroblasts and fibroblast-derived therapeutics to the GI tract using encapsulation materials and enteric coatings.

The disclosed platform incorporates multilayer delivery architectures including hydrogels, nanoparticles, protective intermediate layers, and pH-sensitive outer coatings designed to bypass gastric acid and digestive enzymes before releasing therapeutic payloads in targeted regions of the intestine.

The application covers potential oral administration across chronic gastrointestinal disorders including inflammatory bowel disease, irritable bowel syndrome, peptic ulcer disease, celiac disease, gastritis, Crohn's disease, ulcerative colitis, and gastrointestinal cancers.

"A successful oral fibroblast therapeutic could meaningfully change the treatment paradigm by offering a more accessible, non-invasive approach designed to deliver regenerative and immunomodulatory activity directly to the gastrointestinal tract," said Pete O'Heeron, founder and chief executive officer of FibroBiologics.

The Houston-based clinical-stage biotechnology company claims to hold more than 270 U.S. and international patents issued and pending across various clinical pathways. The company focuses on developing therapeutics using fibroblasts and fibroblast-derived materials for chronic diseases.